{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:06:01Z","timestamp":1790802361545,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["ALFGBG"],"award-info":[{"award-number":["ALFGBG"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["21 1486 Pj"],"award-info":[{"award-number":["21 1486 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["24 3826 Pj"],"award-info":[{"award-number":["24 3826 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["20 0156 F"],"award-info":[{"award-number":["20 0156 F"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejca.2026.117048","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:11:39Z","timestamp":1789085499000},"page":"117048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases"],"prefix":"10.1016","volume":"247","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-8870","authenticated-orcid":false,"given":"Karl","family":"Bj\u00f6rkstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6443-5345","authenticated-orcid":false,"given":"Anna","family":"Fager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8551-3322","authenticated-orcid":false,"given":"Cissi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-5958","authenticated-orcid":false,"given":"Lars","family":"Ny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-4771","authenticated-orcid":false,"given":"Hildur","family":"Helgadottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2026.117048_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1016\/j.ejca.2026.117048_bib2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.117048_bib3","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2026.117048_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2026.117048_bib5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 Trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117048_bib6","first-page":"djaf327","article-title":"Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma","author":"Bj\u00f6rkstr\u00f6m","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2026.117048_bib7","article-title":"Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization","volume":"12","author":"Urban","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2026.117048_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with Pembrolizumab on a Phase II Trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2026.117048_bib9","first-page":"1055","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1","volume":"18","author":"Reck","year":"2023","journal-title":"J Thorac Oncol Publ Int Assoc Study Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.117048_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-Line Nivolumab Plus Ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.117048_bib11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.117048_bib12","first-page":"121","article-title":"Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study","volume":"176","author":"Serra-Bellver","year":"2022","journal-title":"Eur J Cancer Oxf Engl 1990"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:33:12Z","timestamp":1790800392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"alternative-id":["S0959804926008294"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117048","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flipped versus traditional nivolumab plus ipilimumab dosing in patients with melanoma brain metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117048"}}